Besremi

Active Ingredient(s): Ropeginterferon alfa-2b-njft
FDA Approved: * November 12, 2021
Pharm Company: * PHARMAESSENTIA CORP

Ropeginterferon alfa-2b, sold under the brand name Besremi, is a medication used to treat polycythemia vera.[1][2][3][4] It is an interferon.[1][3] It is given by injection.[1][3] The most common side effects include low levels of white blood cells and platelets (blood components that help the blood to clot), muscle and joint pain, tiredness, flu-like symptoms and in... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Besremi 500 ug/ml Subcutaneous Injection

NDC: 73536-500

Labeler:

Pharmaessentia USA